ERBB2 and breast carcinoma: Nevertheless, not all HER2 positive patients benefit from Trastuzumab treatment [11] and around 15% of breast cancer patients relapse after an initial response to trastuzumab-based therapy, suggesting that de novo or acquired resistance to trastuzumab has developed [12].